KR950701932A - 칼슘 및 인산염의 이상 대사를 치료하기 위한 티오-치환된 질소-함유 헤테로사이클릭 포스포네이트 화합물(thio-substituted nitrogen-containing heterocyclic phosphonate compounds for treating abnormal calcium and phosphate metabolism) - Google Patents
칼슘 및 인산염의 이상 대사를 치료하기 위한 티오-치환된 질소-함유 헤테로사이클릭 포스포네이트 화합물(thio-substituted nitrogen-containing heterocyclic phosphonate compounds for treating abnormal calcium and phosphate metabolism)Info
- Publication number
- KR950701932A KR950701932A KR1019940704305A KR19940704305A KR950701932A KR 950701932 A KR950701932 A KR 950701932A KR 1019940704305 A KR1019940704305 A KR 1019940704305A KR 19940704305 A KR19940704305 A KR 19940704305A KR 950701932 A KR950701932 A KR 950701932A
- Authority
- KR
- South Korea
- Prior art keywords
- hydrogen
- substituted
- unsubstituted
- human
- mammal
- Prior art date
Links
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract 6
- 229910019142 PO4 Inorganic materials 0.000 title claims abstract 6
- 229910052791 calcium Inorganic materials 0.000 title claims abstract 6
- 239000011575 calcium Substances 0.000 title claims abstract 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title claims abstract 6
- 239000010452 phosphate Substances 0.000 title claims abstract 6
- 230000004060 metabolic process Effects 0.000 title claims abstract 4
- 230000002159 abnormal effect Effects 0.000 title abstract 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 13
- 241000124008 Mammalia Species 0.000 claims abstract 9
- 238000000034 method Methods 0.000 claims abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 4
- 206010003246 arthritis Diseases 0.000 claims abstract 3
- -1 nitrogen-containing heterocyclic phosphonate compound Chemical class 0.000 claims abstract 3
- 208000001132 Osteoporosis Diseases 0.000 claims abstract 2
- 150000002148 esters Chemical class 0.000 claims abstract 2
- 201000008482 osteoarthritis Diseases 0.000 claims abstract 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 208000021959 Abnormal metabolism Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 230000006371 metabolic abnormality Effects 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 1
- 125000003367 polycyclic group Chemical group 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
- 229940122361 Bisphosphonate Drugs 0.000 abstract 1
- LQHYUUBBIJGBNR-UHFFFAOYSA-N OP(O)(=O)S(O)(=O)=O Chemical compound OP(O)(=O)S(O)(=O)=O LQHYUUBBIJGBNR-UHFFFAOYSA-N 0.000 abstract 1
- 150000004663 bisphosphonates Chemical class 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/5532—Seven-(or more) membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/5765—Six-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 비스포스포네이트, 포스포노알킬포스포네이트, 포스포노카복실레이트 및 포스포노설포네이트를 포함하는 티오-치환된 질소-함유 헤테로사이클릭 포스포네이트 화합물, 및 약학적으로 허용가능한 그의 염 및 에스테르에 관한 것이다. 본 발명은 또한 안전하고 효과적인 양의 조성물에 관한 것이다. 마지막으로, 본 발명은 골다공중 및 관절염, 특히 류마티스성 관절염 및 골관절염을 치료 또는 예방하는 것을 포함하는, 인간 또는 기타 포유동물에서 비정상적인 칼슘 및 인산염 대사를 그 특징으로 하는 병리학적 질환을 치료 또는 예방하기 위한 방법에 관한 것이다. 본 방법은 이렇게 치료해야 하는 인간 또는 다른 포유동물에게 안전하고 효과적인 양의 본 발명 화합물 또는 조성물을 투여하는 것을 포함한다. 이들 화합물은 하기 일반 구조(Ⅰ) 갖는다. :
상기 식에서, m,n,Z,Q,R,R1,R2,R3,R5,R6및 R8은 제1항에 정으한 바와 같다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (15)
- 하기 일반식을 특징으로 하는, 칼슘 및 인산염의 이상 대사를 치료하거나 예방하는데 유용한 티오-치환된 질소-함유 헤테로사이클릭 포스포네이트 화합물, 및 그의 약학적으로 허용가능한 포스폰산 염 또는 에스테르 :상기 식에서, m 및 n은 0내지 10의 정수이고, m과 n의 합은 0 내지 10이고, (a)Z는 0, S 또는 N으롭터 선택된 하나이상의 헤테로훤자(적어도 하나는 N이다)를 함유하는 모노사이클릭 또는 폴리사이클릭 헤테로사이클릭 환 잔기, 바람직하게는 모노사이클릭 혜테로사이클릭 환이고; (b)Q는 공유결합, 0,S,N또는 NR1이며, 바람직하게는 N또는 NR1이고; (c)R은 PO3H2또는 P(0)(OH)R4(여기서 R4는 치환되거나 비치환된 C1-8알킬이다)이며, 바람직하게는 PO3H2또는 P(0)(OH)R4이고 : (d)R1은 존재하지 않거나 각각 독립적으로 -SR6, -R8SR6, 수소, 치환되거나 비치환된 C1-C8알킬, -CO2R3, -NR3 2이고; (e)R2는 Z잔기내의 원자상의 치환체로서, 존재하지 않거나 독립적으로 -SR6, -R8SR6, -CO2R3, -02CR3, -NR3 2, -N(R)3C(0)R3, -OR3, -C(0)N(R3)2, 수소 치환되거나 비치환된 C1-8알킬, 치환되거나 비치환된 아릴, 하이드록시, 치환되거나 비치환된 벤질, 니트로, 또는 이들의 조합물로부터 선택되며, 바람직하게는 -SR6, -R8SR6, -C02R3, 수소, 치환되거나 비치환된 C1-8이고; (f)R3은 각각 독립적으로, 수소, 치환되거나 비치환된 C1-8알킬, 또는 R8SR6로부터 선택되며, 바람직하게는 수소 또는 R8SR6이고; (g)R5는 -SR6, R8SR6, 수소, 하이드록시, 아미노, 할로겐, 또는 치환되거나 비치환된 C1-8알킬로부터 선택되며, 바람직하게는 -SR6, R8SR6, 수소이고; (h)R6은 독립적으로 H, -C(0)R7, -C(S)R7, -C(0)N(R7)2, -C(S)N(R7)2, -C(0)OR7, 또는 -C(S)OR7(여기서, R7은 수소, 또는 치환되거나 비치환된 C1-8알킬이다)로부터 선택되며, 바람직하게는 H, -C(O)R7, -C(S)R7, -C(0)N(R7)2이고; (i)R8은 치환되거나 비치환된 C1-8알킬이고; R1,R2,R3또는 R5중의 하나 이상은 SR6또는 R8SR6이어야 한다.
- 제1항에 있어서, Z가 6원 헤테로사이클릭 환인 화합물.
- 제1항에 있어서, Z가 피리딘, 피리미딘, 피레라딘, 및 디하이드로피리딘인 화합물.
- 제1항에 있어서, Z가 5원 헤테로사이클릭 환인 화합물.
- 제1항에 있어서, Z가 이미다졸, 티아좋, 옥사를, 퍼롤, 푸란, 티오펜, 또는 피롤리딘인 화합물.
- 제1항에 있어서, R1이 -SR6, R8SR6또는 수소인 화합물.
- 제1항에 있어서, R2가 -SR6, R8SR6또는 수소인 화합물.
- 제1항에 있어서, R3가 수소인 화합물.
- 칼슘 및 인산염의 이상 대사에 기인하는 질병의 치료 또는 예방을 필요로하는 인간 또는 다른 포유동물에게 안전효과량의 제1항에 따른 화합물을 투여함을 포함함을 특징으로하는, 칼슘 및 인산염의 이상 대사에 기인하는 질환을 치료하거나 예방하는데 사용되는 약제 제조에서의 제1항에 따른 화합물의 용도.
- 관절염의 치료 또는 예방을 필요로하는 인간 또는 다른 포유동물에게 안전효과량의 제1항에 따른 화합물을 투여함을 포함함을 특징으로하는, 관절염을 치료하거나 예방하는데 사용되는 약제 제조에서의 제1항에 따른 화합물의 용도.
- 칼슘 및 인산염의 이상 대사에 기인하는 질병의 치료 또는 예방을 필요로 하는 인간 또는 다른 포유동물에게 안전효과량의 제1항에 따른 화합물을 투여함을 포함하는, 칼슘 및 인산염의 이상 대사에 기인하는 질병을 치료하거나 예방하는 방법.
- 제11항에 있어서, 상기 인간 또는 포유동물이 골다공증을 앓는 화자인 방법.
- 제11항에 있어시, 상기 인간 또는 다른 포유동물이 관절염을 앓는 환자인 방법.
- 제11항에 있어서, 상기 인간 또는 포유동물이 골관절염을 앓는 환자인 방법.
- 제12항에 있어서, 상기 인간 또는 다른 포유동물이 류마티스성 관절염을 앓는 환자인 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89149092A | 1992-05-29 | 1992-05-29 | |
| US07/891,490 | 1992-05-29 | ||
| US7/891490 | 1992-05-29 | ||
| PCT/US1993/004979 WO1993024500A1 (en) | 1992-05-29 | 1993-05-26 | Thio-substituted nitrogen-containing heterocyclic phosphonate compounds for treating abnormal calcium and phosphate metabolism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR950701932A true KR950701932A (ko) | 1995-05-17 |
| KR100266484B1 KR100266484B1 (ko) | 2000-09-15 |
Family
ID=25398279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019940704305A KR100266484B1 (ko) | 1992-05-29 | 1993-05-26 | 칼슘및인산염의이상대사를치료하기위한티오-치환된질소-함유헤테로사이클릭포스포네이트화합물 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5856314A (ko) |
| EP (1) | EP0642521A1 (ko) |
| JP (1) | JPH07507317A (ko) |
| KR (1) | KR100266484B1 (ko) |
| CN (1) | CN1039327C (ko) |
| AU (1) | AU666741B2 (ko) |
| CA (1) | CA2136820C (ko) |
| CZ (1) | CZ295994A3 (ko) |
| FI (1) | FI945595A0 (ko) |
| HU (1) | HUT69731A (ko) |
| IL (1) | IL105832A (ko) |
| MX (1) | MX9303249A (ko) |
| NO (1) | NO305398B1 (ko) |
| NZ (1) | NZ253526A (ko) |
| PL (1) | PL175046B1 (ko) |
| RU (1) | RU2124019C1 (ko) |
| SG (1) | SG47603A1 (ko) |
| SK (1) | SK144694A3 (ko) |
| WO (1) | WO1993024500A1 (ko) |
| ZA (1) | ZA933766B (ko) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1175433B1 (en) | 1999-05-04 | 2005-08-03 | Strakan International Limited | Androgen glycosides and androgenic activity thereof |
| WO2001044257A1 (en) * | 1999-12-17 | 2001-06-21 | Ariad Pharmaceuticals, Inc. | Proton pump inhibitors |
| JP2003519183A (ja) * | 2000-01-04 | 2003-06-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 心臓および動脈の石灰化を抑制する低用量ビスホスホネートの使用 |
| AU2003211022A1 (en) * | 2002-02-19 | 2003-09-09 | Ilex Products, Inc. | Aminodiphosphonate apolipoprotein e modulators |
| WO2005090370A1 (en) | 2004-02-05 | 2005-09-29 | The Regents Of The University Of California | Pharmacologically active agents containing esterified phosphonates and methods for use thereof |
| US20070003608A1 (en) * | 2005-04-08 | 2007-01-04 | Almond Merrick R | Compounds, compositions and methods for the treatment of viral infections and other medical disorders |
| JP2008535862A (ja) | 2005-04-08 | 2008-09-04 | キメリクス，インコーポレイテッド | ポックスウイルス感染の治療のための化合物、組成物および方法 |
| PT2155851E (pt) | 2007-06-06 | 2014-07-28 | Basf Se | Uso de um polímero de n-vinilimidazol para o melhoramento das propriedades determinantes de valor de soluções biológicas ermentadas |
| EP3085377A1 (en) * | 2008-01-25 | 2016-10-26 | Chimerix, Inc. | Methods of treating viral infections |
| WO2011011519A1 (en) | 2009-07-21 | 2011-01-27 | Chimerix, Inc. | Compounds, compositions and methods for treating ocular conditions |
| CA2770282A1 (en) | 2009-08-03 | 2011-02-10 | Chimerix, Inc. | Composition and methods of treating viral infections and viral induced tumors |
| WO2011100698A2 (en) | 2010-02-12 | 2011-08-18 | Chimerix, Inc. | Methods of treating viral infection |
| WO2011139709A2 (en) | 2010-04-26 | 2011-11-10 | Chimerix, Inc. | Methods of treating retroviral infections and related dosage regimes |
| RU2506085C1 (ru) * | 2013-01-30 | 2014-02-10 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") | Тетраэтил-2-(2,2,6,6-тетраметилпиперидин-4-иламино)-этилен-1,1-бисфосфонат, обладающий противоопухолевой активностью |
| DE202015000809U1 (de) | 2015-02-02 | 2015-02-16 | Basf Se | Copolymere enthaltend Alkylaminoalkylalkoxy(meth)acrylate und deren Verwendung zur Wasserbehandlung |
| CA3028343A1 (en) * | 2016-06-03 | 2017-12-07 | Biovinc, Llc. | Bisphosphonate quinolone conjugates and uses thereof |
| US10865220B2 (en) | 2016-06-03 | 2020-12-15 | Biovinc, Llc | Bisphosphonate quinolone conjugates and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4208401A (en) * | 1977-08-19 | 1980-06-17 | Colgate-Palmolive Company | Quaternary ammonium alkylene diphosphonate anti-calculus agents |
| DE2745083C2 (de) * | 1977-10-07 | 1985-05-02 | Henkel KGaA, 4000 Düsseldorf | Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung |
| DE2835492A1 (de) * | 1978-08-12 | 1980-02-21 | Bayer Ag | 2-cycloalkyl-pyrimidin(5)yl-(thiono) (thiol)-phosphor-(phosphon)-saeureester bzw. -esteramide, verfahren zu ihrer herstellung sowie ihre verwendung als insektizide, akarizide und nematizide |
| DE3016289A1 (de) * | 1980-04-28 | 1981-10-29 | Henkel KGaA, 4000 Düsseldorf | Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren |
| FR2531088B1 (fr) * | 1982-07-29 | 1987-08-28 | Sanofi Sa | Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation |
| US4588711A (en) * | 1982-11-22 | 1986-05-13 | The Dow Chemical Company | Insecticidal phosphorus derivatives of 6-cycloalkyl-4-pyrimidinols |
| FR2558837B1 (fr) * | 1984-01-26 | 1986-06-27 | Sanofi Sa | Derives de l'acide methylenediphosphonique, procede d'obtention et medicaments antirhumatismaux les contenant |
| DE3428524A1 (de) * | 1984-08-02 | 1986-02-13 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| US4687768A (en) * | 1984-12-21 | 1987-08-18 | The Procter & Gamble Company | Certain hexahydroindan-2,2-diphosphonic acids useful in treating diseases associated with abnormal calcium and phosphate metabolism |
| US5104863A (en) * | 1984-12-21 | 1992-04-14 | The Procter & Gamble Company | Certain bicycloalkane and azabicycloalkane-1,1-diphosphonic acid derivatives useful for treating diseases associated with abnormal calcium and phosphate metabolism |
| IL77243A (en) * | 1984-12-21 | 1996-11-14 | Procter & Gamble | Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds |
| US4902679A (en) * | 1985-12-13 | 1990-02-20 | Norwich Eaton Pharmaceuticals, Inc. | Methods of treating diseases with certain geminal diphosphonates |
| EP0243173B1 (en) * | 1986-04-24 | 1991-06-26 | Fujisawa Pharmaceutical Co., Ltd. | New diphosphonic acid compounds, processes for the preparation thereof and pharmaceutical composition comprising the same |
| DE3776880D1 (de) * | 1986-11-21 | 1992-04-02 | Ciba Geigy Ag | Neue substituierte alkandiphosphonsaeuren. |
| DE3640938A1 (de) * | 1986-11-29 | 1988-06-01 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel |
| US4868164A (en) * | 1986-12-19 | 1989-09-19 | Norwich Eaton Pharmaceuticals, Inc. | Octahydro-pyridine diphosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
| US5071840A (en) * | 1986-12-19 | 1991-12-10 | Norwich Eaton Pharmaceuticals, Inc. | Certain heterocyclic substituted diphosphonate compounds pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism |
| IL86951A (en) * | 1987-07-06 | 1996-07-23 | Procter & Gamble Pharma | Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them |
| EP0320455B1 (de) * | 1987-12-11 | 1993-06-09 | Ciba-Geigy Ag | Araliphatylaminoalkandiphosphonsäuren |
| US4933472A (en) * | 1988-04-08 | 1990-06-12 | Yamanouchi Pharmaceutical Co., Ltd. | Substituted aminomethylenebis(phosphonic acid) derivatives |
| TW198039B (ko) * | 1988-11-28 | 1993-01-11 | Ciba Geigy Ag | |
| DE69002328T2 (de) * | 1989-04-03 | 1993-12-09 | Upjohn Co | Geminale bisphosphonsäuren und deren derivate als antiarthritische mittel. |
| DE4011777A1 (de) * | 1989-04-14 | 1990-10-18 | Ciba Geigy Ag | N-trisubstituierte aminoalkandiphosphonsaeuren |
| US4922007A (en) * | 1989-06-09 | 1990-05-01 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof |
| WO1991010646A1 (en) * | 1990-01-12 | 1991-07-25 | Rhone-Poulenc Rorer International (Holdings) Inc. | 1-azetidyl and 1-hexamethylenimine alkyl or aryl bisphosphonic acids and their use as pharmacological agents |
| US5763611A (en) * | 1992-05-29 | 1998-06-09 | The Procter & Gamble Company | Thio-substituted cyclic phosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
| NZ253524A (en) * | 1992-05-29 | 1997-01-29 | Procter & Gamble Pharma | Sulphur-containing phosphonate derivatives and medicaments (for treating abnormal calcium and phosphate metabolism) |
| CZ297094A3 (en) * | 1992-05-29 | 1995-12-13 | Procter & Gamble Pharma | Phosphate compounds containing quaternary nitrogen, their use and pharmaceutical compositions containing thereof |
-
1993
- 1993-05-26 SG SG1996003070A patent/SG47603A1/en unknown
- 1993-05-26 JP JP6500724A patent/JPH07507317A/ja active Pending
- 1993-05-26 CZ CZ942959A patent/CZ295994A3/cs unknown
- 1993-05-26 KR KR1019940704305A patent/KR100266484B1/ko not_active IP Right Cessation
- 1993-05-26 NZ NZ253526A patent/NZ253526A/en unknown
- 1993-05-26 CA CA002136820A patent/CA2136820C/en not_active Expired - Fee Related
- 1993-05-26 PL PL93306141A patent/PL175046B1/pl unknown
- 1993-05-26 AU AU43919/93A patent/AU666741B2/en not_active Ceased
- 1993-05-26 HU HU9403407A patent/HUT69731A/hu unknown
- 1993-05-26 EP EP93914153A patent/EP0642521A1/en not_active Ceased
- 1993-05-26 RU RU94046146A patent/RU2124019C1/ru active
- 1993-05-26 SK SK1446-94A patent/SK144694A3/sk unknown
- 1993-05-26 WO PCT/US1993/004979 patent/WO1993024500A1/en not_active Application Discontinuation
- 1993-05-28 IL IL10583293A patent/IL105832A/en not_active IP Right Cessation
- 1993-05-28 ZA ZA933766A patent/ZA933766B/xx unknown
- 1993-05-29 CN CN93108277A patent/CN1039327C/zh not_active Expired - Fee Related
- 1993-05-31 MX MX9303249A patent/MX9303249A/es not_active Application Discontinuation
-
1994
- 1994-05-09 US US08/240,303 patent/US5856314A/en not_active Expired - Fee Related
- 1994-11-24 NO NO944501A patent/NO305398B1/no not_active IP Right Cessation
- 1994-11-28 FI FI945595A patent/FI945595A0/fi unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HU9403407D0 (en) | 1995-02-28 |
| ZA933766B (en) | 1994-01-20 |
| KR100266484B1 (ko) | 2000-09-15 |
| IL105832A (en) | 1998-08-16 |
| CA2136820A1 (en) | 1993-12-09 |
| RU2124019C1 (ru) | 1998-12-27 |
| PL175046B1 (pl) | 1998-10-30 |
| IL105832A0 (en) | 1993-09-22 |
| AU4391993A (en) | 1993-12-30 |
| WO1993024500A1 (en) | 1993-12-09 |
| US5856314A (en) | 1999-01-05 |
| FI945595A (fi) | 1994-11-28 |
| FI945595A0 (fi) | 1994-11-28 |
| AU666741B2 (en) | 1996-02-22 |
| NZ253526A (en) | 1997-01-29 |
| JPH07507317A (ja) | 1995-08-10 |
| CN1039327C (zh) | 1998-07-29 |
| EP0642521A1 (en) | 1995-03-15 |
| CA2136820C (en) | 1997-09-09 |
| MX9303249A (es) | 1994-05-31 |
| CN1085907A (zh) | 1994-04-27 |
| SK144694A3 (en) | 1995-06-07 |
| RU94046146A (ru) | 1996-11-27 |
| NO305398B1 (no) | 1999-05-25 |
| HUT69731A (en) | 1995-09-28 |
| NO944501L (no) | 1995-01-27 |
| CZ295994A3 (en) | 1995-10-18 |
| SG47603A1 (en) | 1998-04-17 |
| NO944501D0 (no) | 1994-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR950701932A (ko) | 칼슘 및 인산염의 이상 대사를 치료하기 위한 티오-치환된 질소-함유 헤테로사이클릭 포스포네이트 화합물(thio-substituted nitrogen-containing heterocyclic phosphonate compounds for treating abnormal calcium and phosphate metabolism) | |
| RU94046137A (ru) | Фосфонсульфонатные соединения для лечения аномального кальциевого и фосфатного обмена, фармацевтическая композиция | |
| KR930003912A (ko) | 울혈성 심장 마비 치료법 | |
| FI945599A0 (fi) | Fosfonokarboksylaattiyhdisteitä epänormaalin kalsium- ja fosfaattiaineenvaihdunnan hoitamiseksi | |
| ES2100222T3 (es) | Derivados del acido aminoalcansulfonico y compuestos farmaceuticos a utilizar para prevenir o tratar afecciones cardiacas. | |
| DE69029693D1 (de) | Hydantoin- oder Imidazolidintrionderivate zur Vorbeugung oder Behandlung von Niereninsuffizienz | |
| KR950701929A (ko) | 비정상적인 칼슘 및 인산염 대사를 치료하기 위한 황-함유 포스포네이트 화합물(sulfur-containing phosphonate compounds for treating abnormal calcium and phosphate metabolism) | |
| NO307406B1 (no) | Anvendelse av 1-aryl-3-(4-piperidyl)-indolderivater ved behandling av kognitive forstyrrelser | |
| KR930017882A (ko) | 아미노 벤조산 유도체 | |
| FI945592A0 (fi) | Fosfonosulfonaattiyhdisteitä epänormaalin kalsium- ja fosfaattiaineenvaihdunnan hoitamiseksi | |
| KR950701928A (ko) | 비정상적인 칼슘 및 인산염 대사를 치료하기 위한 티오-치환된 환상 포스포네이트 화합물(thio-substituted cyclic phosphonate compounds, for treating abnormal calcium and phosphate metabolism) | |
| DE69327240D1 (de) | Quaternäre stickstoff-enthaltende phosphonat-verbindungen zur behandlung abnormalen calzium-und phosphat-metabolismus | |
| RU94046103A (ru) | Содержащие четвертичный азот фосфонатные соединения для лечения аномального кальциевого и фосфатного метаболизма, фармацевтическая композиция, способ лечения | |
| KR910011820A (ko) | Ltb4 합성 저해제 | |
| US4252821A (en) | Method for treating ulcers | |
| RU94046139A (ru) | Содержащие четвертичный азот фосфанатные соединения для лечения аномального кальциевого и фосфатного метаболизма, фармацевтическая композиция | |
| RU94046138A (ru) | Тиозамещенные циклические фосфонатные соединения для лечения аномального кальциевого и фосфатного метаболизма, фармацевтическая композиция, способ лечения | |
| MX9605153A (es) | Agentes farmaceuticos para el tratamiento de enfermedades inflamatorias cronicas y agudas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| LAPS | Lapse due to unpaid annual fee |